A medicine prescribed routinely to strengthen bone is being tested for a completely different biological purpose: disturbing the latent cellular reservoir that prevents antiretroviral therapy from curing HIV. ACTG has opened STAIR-HIV, also known as A5428, a small randomized, double-blind and placebo-controlled study that will enroll 30 adults whose virus remains suppressed on ART. Twenty participants will receive 70 mg of oral alendronate once weekly for 24 weeks while 10 receive matched placebo, with researchers examining whether the drug changes the size or activity of persistent HIV reservoirs.
The study does not ask whether alendronate can replace antiretroviral therapy, and participants remain on ART throughout. Instead, investigators are exploiting unexpected laboratory evidence that aminobisphosphonates can reactivate transcription from latent HIV while simultaneously influencing immune effector cells. The experiment is deliberately small because its first objective is mechanistic: determine whether a well-characterized drug used for osteoporosis can reproducibly perturb HIV persistence enough in living patients to justify incorporation into a larger remission or cure strategy.
Why does HIV return when effective antiretroviral therapy is stopped?
Modern ART can suppress circulating HIV to levels below routine detection and allow the immune system to recover, but it does not eliminate every infected cell. Some long-lived CD4 T cells contain integrated HIV DNA that remains transcriptionally silent or only minimally active while treatment continues.
These cells form part of the latent reservoir. Because they are not producing large amounts of viral protein, they can remain relatively invisible to both antiretroviral drugs, which act during stages of viral replication, and immune cells seeking actively infected targets. When ART stops, a fraction of these cells can reactivate and release virus, allowing systemic infection to rebound.
This is why a person can maintain an undetectable viral load for years and still require continued treatment. A scalable HIV cure or durable treatment-free remission needs either to eliminate enough reservoir cells, permanently silence them, enhance immune control after ART withdrawal or combine several of those strategies.
Why would alendronate, of all drugs, affect HIV latency?
Alendronate belongs to the nitrogen-containing bisphosphonate family. These drugs inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, which is central to their effect on bone-resorbing osteoclasts but also changes metabolites involved in immune-cell signaling.
Laboratory researchers discovered that aminobisphosphonates including alendronate, pamidronate and zoledronate could induce transcription from latent HIV in cells obtained from people whose virus was suppressed by ART. The drugs also activate Vδ2 gamma-delta T cells, cytotoxic immune cells with the potential to recognize and kill infected or otherwise abnormal cells. This combination created an appealing “shock and kill” hypothesis: expose the silent virus and simultaneously stimulate cells capable of attacking the reservoir.
The mechanism remains much less certain in patients than in laboratory systems. Reactivating viral transcription is not equivalent to eliminating the infected cell, and reservoir biology differs substantially among tissues and individuals.
What did the earlier human evidence show before STAIR-HIV?
Researchers previously analyzed stored samples from an older trial in which people with HIV received alendronate for bone health rather than as an HIV cure intervention. Those retrospective analyses provided evidence that the medicine could alter HIV transcription and immune activation in some participants, giving investigators a rare opportunity to explore in-vivo biology before launching a dedicated latency trial.
The result was not evidence of a cure. When investigators used an intact proviral DNA assay to estimate reservoir size, they did not demonstrate a statistically convincing reduction attributable to alendronate. The analysis involved small and uneven groups, and variability was sufficiently high that the investigators specifically cautioned against drawing firm reservoir conclusions.
That negative point is exactly why STAIR-HIV matters. The earlier work suggested biological activity but could not establish whether deliberately treating a controlled HIV population with alendronate produces a reproducible effect on the reservoir. A prospective randomized trial is a cleaner way to ask the question.
Why only 30 participants if HIV cure research is such a large problem?
STAIR-HIV is part of ACTG’s Small Clinical Trials Advancing HIV Remission and Cure programme, which was created for intensive mechanistic studies that may require specialized assays and procedures but do not initially need hundreds of patients. The programme aims to identify sufficiently promising biological signals before committing to large multicenter trials.
The 2:1 randomization gives researchers twice as many alendronate-treated participants as placebo recipients while preserving a blinded comparator. Eligible adults are expected to have been on ART for at least one year but less than 10 years and remain virologically suppressed, providing a population in which changes in reservoir markers can be studied without the confounding effect of uncontrolled viral replication.
If the trial shows no meaningful latency or reservoir effect, the programme can stop with relatively limited patient exposure and cost. If it produces a strong mechanistic signal, investigators can then design a larger combination study around the specific effect observed.
Why might alendronate need to be combined with another therapy even if it works?
Latency reversal alone may be insufficient. An infected cell can begin transcribing HIV without dying, and chronic infection can leave conventional HIV-specific immune responses exhausted or numerically inadequate. Many “shock and kill” strategies therefore envision combining a latency-reversing drug with therapeutic vaccination, broadly neutralizing antibodies, engineered T cells or other immune interventions capable of eliminating newly exposed reservoir cells.
Alendronate is particularly interesting because it may contribute to both sides of the equation through HIV transcription and gamma-delta T-cell activation, but the magnitude may still be too small for stand-alone reservoir reduction. The preclinical investigators themselves suggested that combination with therapeutic vaccination could deserve study.
A familiar medicine also brings practical advantages. Alendronate already has decades of human safety experience, established manufacturing and inexpensive oral dosing, so repurposing could avoid much of the chemistry and early toxicology work required for a completely new latency-reversing agent.
What would count as success for STAIR-HIV?
A successful first study does not need to show that participants can stop ART permanently. It needs to demonstrate that weekly alendronate produces a measurable, reproducible biological effect on latent HIV or reservoir characteristics beyond placebo while remaining tolerable.
Investigators can then ask whether that effect is large enough to combine with an immune intervention. Conversely, a failure to reduce the reservoir would not necessarily mean the drug does nothing biologically if it reliably increases viral transcription; it could mean that exposure and immune clearance need to be separated into a two-step strategy.
This makes STAIR-HIV a useful example of modern drug repurposing. The osteoporosis indication tells clinicians what alendronate normally does. The HIV trial is asking whether one of the same metabolic pathways the medicine perturbs can be exploited for an entirely different purpose.
The idea is counterintuitive enough to attract attention, but the evidence threshold should remain strict. An inexpensive weekly pill would be an unusually scalable component of an HIV-remission strategy, yet the first dedicated randomized study contains only 30 people. Its value lies in determining whether an intriguing laboratory observation is sufficiently real in patients to justify the much larger cure experiments that would have to follow.
